Endo International — Shareholder Meeting (June 2014)
12 slides from Endo International's shareholder meeting presentation, Jun 10, 2014
Slide 1: Endo Annual General Meeting of Shareholders, June 10, 2014
Exhibit 99.1 Exhibit Endo Annual June ©201410, International Endo General 99.1 2014Pharmaceuticals Meeting plc of Shareholders Inc. All rights reserved.
Slide 2: Forward Looking Statements
Forward Statements forward reliance factors, under Electronic financial looking could any applicable This accepted K GAAP 1© presentation. 2014 filings, filed forward presentation cause the financial Endo with as statements. statements on looking Looking in results caption as more Document securitie
Slide 3: Today's Agenda
Today’s Company First Near 2© 2014 Year Term Endo Agenda Strategy Progress Objectives Pharmaceuticals and Progress Inc. All 2014 rights Financial reserved. Guidance Summary and Q&A
Slide 4: Endo's Strategic Focus
Endo’s Build Focus Participate Transform Continue Maximize 3@2014aon strategic leading Endo maximizing our shareholder operating in commitment Pharmaceuticals specialty global direction model the specialty value areas value totoby offering serving maximize Inc. of adapting healthcare each Allour abo
Slide 5: Endo's Lean, Streamlined Operating Model
Endo Lean, Performance M&A Streamlined 4© 2014Operating efficient an Endo important and metrics Pharmaceuticals operating Model diversified component aligned model organization with Inc. of building shareholder All rights with &reserved. growing quick interests decision the business makinglong term
Slide 6: Delivering Progress in the First Year
Delivering Strengthened Implemented Closed Increased Completed Agreements Enhanced 5© 2014 Endo Boca strategic capital Our the in Pharmacal, Pharmaceuticals atalent principle divestiture Lean Strategy structure focus and Operating organization to –Paladin of Aflexibility settle Year HealthTronics In
Slide 7: Near Term Priorities
Near Meet Drive Complete Enhance 6© 2014 Term Financial Organic Endo Continued 2Priorities 3Pharmaceuticals Near Growth Targets term Focus Through Accretive, on Quality, Inc. OurAll Value Core rights Compliance creating Business reserved. Transactions and Establish Risk NewIncrease Corporate ValueSt
Slide 8: 2014 Financial Guidance
2014 Measure Revenues Adjusted Reported 7© 2014 Financial Endo 2014 Gross Operating (GAAP) $2.55B Pharmaceuticals Guidance Guidance Margin $2.64B Earnings Expenses 63%(Loss) toYear Inc. 65% All per overrights share yearreserved. ($1.35) low double to ($1.10) digit percentage Adjusted Diluted decreas
Slide 9: Summary: Executing Strategy
Summary Executing Convertible LIDODERM® Deploying Sale Boca Enhancing 8© 2014 ofPharmacal, Endo HealthTronics Wrap strategy capital operational Notes Pharmaceuticals loss up Paladin to Mesh announced of accretive, exclusivity focus liability Labson Inc. in and value organic June All Sumavel® creatin
Slide 10: Appendix
©2014 Endo Pharmaceuticals Inc. All rights reserved. Appendix
Slide 11: Reconciliation of Projected GAAP to Adjusted Diluted EPS
For an Reconciliation Ending Lower Projected Upfront Basic Tax $3.60 The Certain Includes ©2014 10 effect company’s to $3.85 explanation End Endo December of and Diluted all GAAP of the of completed Diluted milestone pre Pharmaceuticals above Range of guidance weighted tax diluted Non Projected 31,
Slide 12: Endo Annual General Meeting of Shareholders, June 10
Endo10, Annual June ©2014International Endo General 2014Pharmaceuticals Meeting plc of Shareholders Inc. All rights reserved.